Compare · ATRC vs SYK
ATRC vs SYK
Side-by-side comparison of AtriCure Inc. (ATRC) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATRC and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $122.63B, about 69.3x ATRC ($1.77B).
- Over the past year, ATRC is up 19.4% and SYK is down 17.5% - ATRC leads by 36.9 points.
- ATRC has been more active in the news (6 items in the past 4 weeks vs 3 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 14 for ATRC).
- Company
- AtriCure Inc.
- Stryker Corporation
- Price
- $34.90-1.97%
- $319.74-3.44%
- Market cap
- $1.77B
- $122.63B
- 1M return
- +24.78%
- +2.90%
- 1Y return
- +19.40%
- -17.49%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- News (4w)
- 6
- 3
- Recent ratings
- 14
- 25
AtriCure Inc.
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest ATRC
- President, CEO, & Director Carrel Michael H was granted 636 shares, increasing direct ownership by 0.08% to 779,134 units (SEC Form 4)
- Chief Scientific Officer Doraiswamy Vinayak was granted 636 shares, increasing direct ownership by 0.69% to 92,511 units (SEC Form 4)
- Chief Legal Officer Dahlquist Karl S. was granted 636 shares, increasing direct ownership by 0.66% to 96,689 units (SEC Form 4)
- Chief Operating Officer Seith Douglas J was granted 527 shares, increasing direct ownership by 0.23% to 229,867 units (SEC Form 4)
- Chief Technical Officer Privitera Salvatore was granted 636 shares, increasing direct ownership by 0.40% to 158,684 units (SEC Form 4)
- AtriCure to Announce Second Quarter 2026 Financial Results
- SEC Form SD filed by AtriCure Inc.
- AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
- Director Prange Karen sold $85,950 worth of shares (3,000 units at $28.65), decreasing direct ownership by 10% to 26,373 units (SEC Form 4)
- Director Prange Karen was granted 6,144 shares, increasing direct ownership by 26% to 29,373 units (SEC Form 4)
Latest SYK
- Stryker expands Mako robotics portfolio with full market release of Mako RPS
- BMO Capital Markets initiated coverage on Stryker with a new price target
- Stryker to announce second quarter 2026 financial results
- Stryker Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Stryker partners with professional golfer Shane Lowry to spotlight the caregiver journey in joint replacement
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)